KR101947289B1 - 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제 - Google Patents

신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제 Download PDF

Info

Publication number
KR101947289B1
KR101947289B1 KR1020177002160A KR20177002160A KR101947289B1 KR 101947289 B1 KR101947289 B1 KR 101947289B1 KR 1020177002160 A KR1020177002160 A KR 1020177002160A KR 20177002160 A KR20177002160 A KR 20177002160A KR 101947289 B1 KR101947289 B1 KR 101947289B1
Authority
KR
South Korea
Prior art keywords
group
ethynyl
methyl
pyrrolo
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177002160A
Other languages
English (en)
Korean (ko)
Other versions
KR20170016510A (ko
Inventor
다카시 미즈타니
치호코 요시무라
히토미 곤도
마코토 기타데
슈이치 오쿠보
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20170016510A publication Critical patent/KR20170016510A/ko
Application granted granted Critical
Publication of KR101947289B1 publication Critical patent/KR101947289B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020177002160A 2014-06-24 2015-06-24 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제 Expired - Fee Related KR101947289B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2014-129740 2014-06-24
JP2014129740 2014-06-24
JP2015024785 2015-02-10
JPJP-P-2015-024785 2015-02-10
PCT/JP2015/068218 WO2015199136A1 (ja) 2014-06-24 2015-06-24 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤

Publications (2)

Publication Number Publication Date
KR20170016510A KR20170016510A (ko) 2017-02-13
KR101947289B1 true KR101947289B1 (ko) 2019-02-12

Family

ID=54938214

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177002160A Expired - Fee Related KR101947289B1 (ko) 2014-06-24 2015-06-24 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제

Country Status (21)

Country Link
US (2) US9963456B2 (https=)
EP (1) EP3103802B1 (https=)
JP (1) JP6192741B2 (https=)
KR (1) KR101947289B1 (https=)
CN (1) CN106661031B (https=)
AU (1) AU2015281155B9 (https=)
BR (1) BR112016025835B1 (https=)
CA (1) CA2946833C (https=)
DK (1) DK3103802T3 (https=)
ES (1) ES2656772T3 (https=)
HU (1) HUE037266T2 (https=)
MX (1) MX2016015015A (https=)
MY (1) MY183327A (https=)
NO (1) NO3103802T3 (https=)
PH (1) PH12016502130B1 (https=)
PL (1) PL3103802T3 (https=)
PT (1) PT3103802T (https=)
RU (1) RU2658008C2 (https=)
SG (1) SG11201608441YA (https=)
TW (1) TWI605048B (https=)
WO (1) WO2015199136A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI623316B (zh) * 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
WO2018085818A1 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) * 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018089786A1 (en) * 2016-11-11 2018-05-17 Millennium Pharmaceuticals, Inc. Atg7 inhibitors and the uses thereof
JP7125714B2 (ja) * 2016-12-13 2022-08-25 ヤマサ醤油株式会社 抗ウイルス活性を有する２’－デオキシ－７－デアザプリンヌクレオシド誘導体
EP3740491A1 (en) * 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN108822145B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种磺酰胺类化合物及其制备方法和应用
CN108640945B (zh) * 2018-06-11 2020-10-23 广东工业大学 一种酰胺类化合物及其制备方法与应用
AU2019301697A1 (en) * 2018-07-13 2021-01-07 Il-2Rx, Inc. Compounds, compositions, methods, and uses for treating cancer and immunological disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530027A (ja) 2005-02-04 2008-08-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ｅ１活性化酵素の阻害剤
WO2013108809A1 (ja) 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989430B2 (en) 2005-12-06 2011-08-02 Regents Of The University Of Minnesota Antibacterial agents
EA024006B1 (ru) 2006-02-02 2016-08-31 Миллениум Фармасьютикалз, Инк. Ингибиторы е1 активирующих ферментов
JP2013541587A (ja) 2010-11-05 2013-11-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎｅｄｄ８活性化酵素阻害剤の投与
BR112013017184A2 (pt) 2011-01-07 2016-09-20 Leo Pharma As composto, composição farmacêutica, uso de um composto, e, método para evitar, tratar ou melhorar doenças
WO2013016906A1 (zh) * 2011-07-29 2013-02-07 深圳光启高等理工研究院 人工复合材料和人工复合材料天线

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530027A (ja) 2005-02-04 2008-08-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ｅ１活性化酵素の阻害剤
WO2013108809A1 (ja) 2012-01-19 2013-07-25 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物及びその塩

Also Published As

Publication number Publication date
CA2946833A1 (en) 2015-12-30
ES2656772T3 (es) 2018-02-28
RU2016149319A3 (https=) 2018-06-18
NO3103802T3 (https=) 2018-04-07
RU2016149319A (ru) 2018-06-18
SG11201608441YA (en) 2016-11-29
KR20170016510A (ko) 2017-02-13
PH12016502130A1 (en) 2016-12-19
US10174040B2 (en) 2019-01-08
WO2015199136A1 (ja) 2015-12-30
MY183327A (en) 2021-02-18
EP3103802A4 (en) 2017-03-08
CN106661031A (zh) 2017-05-10
BR112016025835A2 (https=) 2017-08-15
PH12016502130B1 (en) 2016-12-19
AU2015281155A1 (en) 2016-11-03
AU2015281155B9 (en) 2017-11-16
HUE037266T2 (hu) 2018-08-28
US20180162864A1 (en) 2018-06-14
PT3103802T (pt) 2017-12-11
PL3103802T3 (pl) 2018-02-28
BR112016025835B1 (pt) 2022-09-20
EP3103802A1 (en) 2016-12-14
AU2015281155B2 (en) 2017-07-13
TWI605048B (zh) 2017-11-11
JPWO2015199136A1 (ja) 2017-04-27
RU2658008C2 (ru) 2018-06-19
JP6192741B2 (ja) 2017-09-06
MX2016015015A (es) 2017-02-27
TW201625629A (zh) 2016-07-16
CN106661031B (zh) 2019-07-23
US9963456B2 (en) 2018-05-08
US20170066772A1 (en) 2017-03-09
DK3103802T3 (en) 2017-12-11
CA2946833C (en) 2019-03-05
EP3103802B1 (en) 2017-11-08

Similar Documents

Publication Publication Date Title
KR101947289B1 (ko) 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제
KR102934231B1 (ko) 항암제로 유용한 융합 삼환식 화합물
TWI623316B (zh) Antitumor effect enhancer derived from pyrrolopyrimidine compound
JP6553825B2 (ja) 抗がん剤として有用な置換カルボヌクレオシド誘導体
RU2666349C2 (ru) Новое конденсированное пиримидиновое соединение или его соль
JP2021521138A (ja) Ｂｃｌ−２阻害剤
CN111153901A (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
AU2013272701A2 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
CN117858872A (zh) 用于治疗癌症的杂环egfr抑制剂
RU2820445C2 (ru) Соединение-ингибитор jak и его применение
HK1236948A1 (en) Pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, and applications
HK1236948B (zh) 毗咯并嘧啶化合物或其盐、含有其的药物组合物及应用
EP4592286A1 (en) Macrocyclic nitrogen-containing crown ether compound and use thereof as protein kinase inhibitor

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240202

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240202